The Effectiveness of CFT for Reducing Self-criticism in Patients With Complex PTSD: a Single-case Experimental Study

April 28, 2026 updated by: Jannis Kraiss, University of Twente

Effectiveness of Compassion Focused Therapy (CFT) for Reducing Self-criticism in Female Patients With Complex PTSD: a Single-case Experimental Study

PTSD is a mental disorder including psychological symptoms related to severe traumatic event(s). PTSD can negatively affect people's functioning in several life domains. Several effective therapies for the treatment of PTSD have been developed in recent decades. However, these treatments are not effective for every patient. Several studies show that people suffering from PTSD also experience feelings of trauma-related guilt, shame, self-blame and negative self-evaluation. These emotions may contribute to the maintenance cycle of PTSD or even become worse over time. In particularly in patients with trauma who have been exposed to repeated traumatic experiences within the context of interpersonal relationships including childhood sexual/physical abuse and domestic violence. This type of trauma is known as complex PTSD. cPTSD is marked by severe difficulties in problems with self and emotion-regulation, relationship difficulties and shame. One key factor for reducing self-criticism in individuals might be self-compassion as the antidote to self-criticism and shame. Compassion focused therapy by Paul Gilbert focuses specifically on increasing self-compassion. Although some studies show promising results of CFT in patients with cPTSS, the effectiveness for this group has not yet been sufficiently examined. Therefore, this Single case experimental design study is conducted with the primary objective of examining the effectiveness of CFT in reducing the primary outcome self-criticism. Secondary outcomes that will be examined are CFT reduces PTSD symptoms and shame and increases self-compassion and well-being.

This SCED study is a noncurrent multiple baseline across subjects study, consisting of three phases with twice-weekly repeated measurements of self-criticism. First the pre-intervention baseline phase, in which participants are randomly assigned to different baseline lengths (either 5, 6 or 7 weeks). The second phase is the subsequent CFT-intervention, consisting of 12 weeks of weekly CFT group sessions with two-weekly assessments of self-criticism. The third phase is follow up for 5 weeks from the end of the intervention, again including two-weekly assessments of self-criticism. By comparing the baseline phases with the intervention and follow-up phases for individual participants, the effectiveness of the CFT intervention on self-critical beliefs can be determined. Changes that occur within participants can be seen as evidence of intervention effectiveness.

Study Overview

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Overijssel
      • Enschede, Overijssel, Netherlands, 7522NB
        • University of Twente

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • The participant is between 18 and 65 years old.
  • Diagnosis of cPTSD and severe problems with self criticism (as diagnosed by an experienced clinican).
  • The participant gives consent to participate in the study using the online informed consent procedure.
  • Sufficient Dutch language proficiency and average intelligence.
  • The participant has an e-mail address and is in possession of a smartphone or tablet with access to the internet.
  • The participant is willing to complete twice-weekly questionnaires for up to 24 weeks.

Exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Compassion-focused therapy (CFT)
The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-criticism
Time Frame: Up to 24 weeks
Measured with the Forms of Self-Criticizing/Attacking and Self-Reassuring Scale (FSCRS-SF). It contains 14 items and is a valid and sensitive measurement scale with adequate psychometric properties including structural validity, convergent validity and sensitivity to change. Higher scores indicate more self-criticism and more self-reassurance. Mean scores range from 0 to 4.
Up to 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD symptoms
Time Frame: Posttest (T1); 3 months after baseline
The Post Traumatic Checklist Scale (PCL-5) measures the extent in which participant's experienced PTSD symptoms in the past month. It contains 20 items and is a valid and reliable questionnaire for screening and assessing PTSD in clinical practice. Higher scores indicate more PTSD symptoms. Total scores range from 0 to 80.
Posttest (T1); 3 months after baseline
Self-compassion
Time Frame: Posttest (T1); 3 months after baseline
Self compassion will be measured with the Self-Compassion Scale-Short Form (SCS-SF). The SCS-SF contains 12 items. Higher scores reflect higher levels of self-compassion. The Dutch version of the SCS-SF has adequate psychometric qualities. Mean scores range from 0 to 5.
Posttest (T1); 3 months after baseline
Well-being
Time Frame: Posttest (T1); 3 months after baseline
The 14-item Mental Health Continuum-Short Form (MHC-SF) measures well-being. Higher scores indicate more well-being. The MHC-SF has shown very good psychometric properties in previous studies. Mean scores range from 0 to 5.
Posttest (T1); 3 months after baseline
Shame
Time Frame: Posttest (T1); 3 months after baseline
Experiences of Shame Scale (ESS) is the version of Andrews' Experience of Shame Scale (ESS). The ESS distinguishes between characteristic, behavioral and physical shame. The test consists of 25 statements related to shame. Mean scores rang from 1 to 4 with higher scores indicating more Shame.
Posttest (T1); 3 months after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2023

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

March 13, 2023

First Submitted That Met QC Criteria

March 28, 2023

First Posted (Actual)

March 30, 2023

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Posttraumatic Stress Disorder

Clinical Trials on Compassion-focused therapy (CFT) for complex PTSD

Subscribe